nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—CYP2C9—Capecitabine—kidney cancer	0.0798	0.458	CbGbCtD
Cyclizine—CYP2C9—Paclitaxel—kidney cancer	0.05	0.287	CbGbCtD
Cyclizine—CYP2C9—Sorafenib—kidney cancer	0.0444	0.255	CbGbCtD
Cyclizine—SULT1E1—Estrogen metabolism—GSTM1—kidney cancer	0.0121	0.0847	CbGpPWpGaD
Cyclizine—SULT1E1—Estrogen metabolism—CYP1A1—kidney cancer	0.0115	0.0803	CbGpPWpGaD
Cyclizine—SULT1E1—Tamoxifen metabolism—CYP1A1—kidney cancer	0.0102	0.071	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—ACY1—kidney cancer	0.00973	0.0679	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTT1—kidney cancer	0.00536	0.0374	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—ALDH1A1—kidney cancer	0.00533	0.0372	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTP1—kidney cancer	0.00371	0.0259	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTM1—kidney cancer	0.00341	0.0238	CbGpPWpGaD
Cyclizine—Hepatobiliary disease—Sorafenib—kidney cancer	0.00316	0.00468	CcSEcCtD
Cyclizine—Injection site reaction—Capecitabine—kidney cancer	0.00315	0.00466	CcSEcCtD
Cyclizine—SULT1E1—Biological oxidations—GSTT1—kidney cancer	0.00313	0.0219	CbGpPWpGaD
Cyclizine—Eye disorder—Erlotinib—kidney cancer	0.00311	0.00461	CcSEcCtD
Cyclizine—Chills—Everolimus—kidney cancer	0.0031	0.00459	CcSEcCtD
Cyclizine—Depressed level of consciousness—Capecitabine—kidney cancer	0.00306	0.00453	CcSEcCtD
Cyclizine—Nervous system disorder—Pazopanib—kidney cancer	0.00305	0.00452	CcSEcCtD
Cyclizine—Hepatobiliary disease—Sunitinib—kidney cancer	0.00304	0.0045	CcSEcCtD
Cyclizine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—kidney cancer	0.00303	0.0212	CbGpPWpGaD
Cyclizine—Mental disorder—Everolimus—kidney cancer	0.00302	0.00448	CcSEcCtD
Cyclizine—Skin disorder—Pazopanib—kidney cancer	0.00302	0.00447	CcSEcCtD
Cyclizine—Erythema—Everolimus—kidney cancer	0.00301	0.00445	CcSEcCtD
Cyclizine—Chills—Erlotinib—kidney cancer	0.00299	0.00443	CcSEcCtD
Cyclizine—Insomnia—Temsirolimus—kidney cancer	0.00298	0.00442	CcSEcCtD
Cyclizine—Connective tissue disorder—Sorafenib—kidney cancer	0.00294	0.00437	CcSEcCtD
Cyclizine—SULT1E1—Biological oxidations—PTGS1—kidney cancer	0.00294	0.0205	CbGpPWpGaD
Cyclizine—Somnolence—Temsirolimus—kidney cancer	0.00293	0.00435	CcSEcCtD
Cyclizine—Mental disorder—Erlotinib—kidney cancer	0.00292	0.00433	CcSEcCtD
Cyclizine—Erythema—Erlotinib—kidney cancer	0.0029	0.0043	CcSEcCtD
Cyclizine—Muscle spasms—Everolimus—kidney cancer	0.00289	0.00428	CcSEcCtD
Cyclizine—Hepatitis—Sunitinib—kidney cancer	0.00288	0.00427	CcSEcCtD
Cyclizine—Bronchospasm—Gemcitabine—kidney cancer	0.00284	0.00421	CcSEcCtD
Cyclizine—Agranulocytosis—Dactinomycin—kidney cancer	0.00284	0.00421	CcSEcCtD
Cyclizine—Connective tissue disorder—Sunitinib—kidney cancer	0.00283	0.0042	CcSEcCtD
Cyclizine—Vision blurred—Everolimus—kidney cancer	0.00283	0.0042	CcSEcCtD
Cyclizine—Blister—Doxorubicin—kidney cancer	0.00283	0.0042	CcSEcCtD
Cyclizine—Pain—Temsirolimus—kidney cancer	0.00282	0.00418	CcSEcCtD
Cyclizine—Constipation—Temsirolimus—kidney cancer	0.00282	0.00418	CcSEcCtD
Cyclizine—Tremor—Everolimus—kidney cancer	0.00282	0.00417	CcSEcCtD
Cyclizine—Insomnia—Pazopanib—kidney cancer	0.00281	0.00416	CcSEcCtD
Cyclizine—Paraesthesia—Pazopanib—kidney cancer	0.00279	0.00413	CcSEcCtD
Cyclizine—Agitation—Everolimus—kidney cancer	0.00276	0.00409	CcSEcCtD
Cyclizine—Somnolence—Pazopanib—kidney cancer	0.00276	0.00409	CcSEcCtD
Cyclizine—Angioedema—Everolimus—kidney cancer	0.00275	0.00407	CcSEcCtD
Cyclizine—Hepatitis—Dactinomycin—kidney cancer	0.00273	0.00405	CcSEcCtD
Cyclizine—Eye disorder—Sunitinib—kidney cancer	0.00269	0.00399	CcSEcCtD
Cyclizine—Pain—Pazopanib—kidney cancer	0.00266	0.00394	CcSEcCtD
Cyclizine—Thrombophlebitis—Capecitabine—kidney cancer	0.00265	0.00393	CcSEcCtD
Cyclizine—Hepatic function abnormal—Capecitabine—kidney cancer	0.00263	0.0039	CcSEcCtD
Cyclizine—Mental disorder—Sorafenib—kidney cancer	0.00263	0.00389	CcSEcCtD
Cyclizine—Convulsion—Vinblastine—kidney cancer	0.00261	0.00387	CcSEcCtD
Cyclizine—Erythema—Sorafenib—kidney cancer	0.00261	0.00387	CcSEcCtD
Cyclizine—Hypertension—Vinblastine—kidney cancer	0.0026	0.00386	CcSEcCtD
Cyclizine—Convulsion—Everolimus—kidney cancer	0.0026	0.00386	CcSEcCtD
Cyclizine—Hypertension—Everolimus—kidney cancer	0.00259	0.00385	CcSEcCtD
Cyclizine—Chills—Sunitinib—kidney cancer	0.00259	0.00384	CcSEcCtD
Cyclizine—Mental disorder—Sunitinib—kidney cancer	0.00253	0.00374	CcSEcCtD
Cyclizine—Erythema—Sunitinib—kidney cancer	0.00251	0.00372	CcSEcCtD
Cyclizine—Muscle spasms—Sorafenib—kidney cancer	0.00251	0.00372	CcSEcCtD
Cyclizine—Trimethaphan—BCHE—kidney cancer	0.0025	0.32	CrCbGaD
Cyclizine—Chills—Dactinomycin—kidney cancer	0.00245	0.00363	CcSEcCtD
Cyclizine—Hepatobiliary disease—Gemcitabine—kidney cancer	0.00244	0.00361	CcSEcCtD
Cyclizine—Hypersensitivity—Temsirolimus—kidney cancer	0.00243	0.0036	CcSEcCtD
Cyclizine—Muscle spasms—Sunitinib—kidney cancer	0.00241	0.00358	CcSEcCtD
Cyclizine—Nervous system disorder—Everolimus—kidney cancer	0.00241	0.00357	CcSEcCtD
Cyclizine—Agranulocytosis—Gemcitabine—kidney cancer	0.00241	0.00357	CcSEcCtD
Cyclizine—Dermatitis bullous—Capecitabine—kidney cancer	0.0024	0.00356	CcSEcCtD
Cyclizine—Connective tissue disorder—Vincristine—kidney cancer	0.0024	0.00355	CcSEcCtD
Cyclizine—Tachycardia—Everolimus—kidney cancer	0.00239	0.00355	CcSEcCtD
Cyclizine—Angioedema—Sorafenib—kidney cancer	0.00238	0.00353	CcSEcCtD
Cyclizine—Skin disorder—Everolimus—kidney cancer	0.00238	0.00353	CcSEcCtD
Cyclizine—Erythema—Dactinomycin—kidney cancer	0.00238	0.00352	CcSEcCtD
Cyclizine—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—kidney cancer	0.00237	0.0166	CbGpPWpGaD
Cyclizine—Asthenia—Temsirolimus—kidney cancer	0.00237	0.00351	CcSEcCtD
Cyclizine—HRH1—IL-4 Signaling Pathway—IL4R—kidney cancer	0.00236	0.0165	CbGpPWpGaD
Cyclizine—Pruritus—Temsirolimus—kidney cancer	0.00233	0.00346	CcSEcCtD
Cyclizine—Jaundice cholestatic—Doxorubicin—kidney cancer	0.00232	0.00344	CcSEcCtD
Cyclizine—Nervous system disorder—Erlotinib—kidney cancer	0.00232	0.00344	CcSEcCtD
Cyclizine—Skin disorder—Erlotinib—kidney cancer	0.0023	0.00341	CcSEcCtD
Cyclizine—Angioedema—Sunitinib—kidney cancer	0.00229	0.0034	CcSEcCtD
Cyclizine—Hypotension—Everolimus—kidney cancer	0.00229	0.0034	CcSEcCtD
Cyclizine—Connective tissue disorder—Gemcitabine—kidney cancer	0.00227	0.00337	CcSEcCtD
Cyclizine—Hypertension—Sorafenib—kidney cancer	0.00225	0.00334	CcSEcCtD
Cyclizine—Asthenia—Pazopanib—kidney cancer	0.00223	0.0033	CcSEcCtD
Cyclizine—Insomnia—Everolimus—kidney cancer	0.00222	0.00329	CcSEcCtD
Cyclizine—Paraesthesia—Vinblastine—kidney cancer	0.00221	0.00328	CcSEcCtD
Cyclizine—Paraesthesia—Everolimus—kidney cancer	0.0022	0.00326	CcSEcCtD
Cyclizine—Pruritus—Pazopanib—kidney cancer	0.0022	0.00326	CcSEcCtD
Cyclizine—Urinary retention—Capecitabine—kidney cancer	0.00219	0.00324	CcSEcCtD
Cyclizine—Somnolence—Everolimus—kidney cancer	0.00218	0.00323	CcSEcCtD
Cyclizine—Dizziness—Temsirolimus—kidney cancer	0.00218	0.00323	CcSEcCtD
Cyclizine—Convulsion—Sunitinib—kidney cancer	0.00217	0.00322	CcSEcCtD
Cyclizine—SULT1E1—Biological oxidations—GSTP1—kidney cancer	0.00217	0.0151	CbGpPWpGaD
Cyclizine—Dyskinesia—Doxorubicin—kidney cancer	0.00217	0.00322	CcSEcCtD
Cyclizine—Hypertension—Sunitinib—kidney cancer	0.00217	0.00321	CcSEcCtD
Cyclizine—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—kidney cancer	0.00216	0.0151	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTP1—kidney cancer	0.00214	0.0149	CbGpPWpGaD
Cyclizine—Insomnia—Erlotinib—kidney cancer	0.00214	0.00317	CcSEcCtD
Cyclizine—Mental disorder—Vincristine—kidney cancer	0.00214	0.00317	CcSEcCtD
Cyclizine—Anaphylactic shock—Sorafenib—kidney cancer	0.00213	0.00316	CcSEcCtD
Cyclizine—Constipation—Vinblastine—kidney cancer	0.00211	0.00312	CcSEcCtD
Cyclizine—Pain—Vinblastine—kidney cancer	0.00211	0.00312	CcSEcCtD
Cyclizine—Pain—Everolimus—kidney cancer	0.0021	0.00311	CcSEcCtD
Cyclizine—Constipation—Everolimus—kidney cancer	0.0021	0.00311	CcSEcCtD
Cyclizine—Nervous system disorder—Sorafenib—kidney cancer	0.00209	0.00309	CcSEcCtD
Cyclizine—Chills—Gemcitabine—kidney cancer	0.00208	0.00308	CcSEcCtD
Cyclizine—Skin disorder—Sorafenib—kidney cancer	0.00207	0.00307	CcSEcCtD
Cyclizine—Headache—Temsirolimus—kidney cancer	0.00207	0.00306	CcSEcCtD
Cyclizine—Dizziness—Pazopanib—kidney cancer	0.00205	0.00304	CcSEcCtD
Cyclizine—Hepatobiliary disease—Paclitaxel—kidney cancer	0.00204	0.00303	CcSEcCtD
Cyclizine—Injection site reaction—Doxorubicin—kidney cancer	0.00203	0.00301	CcSEcCtD
Cyclizine—Pain—Erlotinib—kidney cancer	0.00202	0.003	CcSEcCtD
Cyclizine—Constipation—Erlotinib—kidney cancer	0.00202	0.003	CcSEcCtD
Cyclizine—Erythema—Gemcitabine—kidney cancer	0.00201	0.00299	CcSEcCtD
Cyclizine—Nervous system disorder—Sunitinib—kidney cancer	0.00201	0.00298	CcSEcCtD
Cyclizine—SULT1E1—Biological oxidations—GSTM1—kidney cancer	0.002	0.0139	CbGpPWpGaD
Cyclizine—Skin disorder—Sunitinib—kidney cancer	0.00199	0.00295	CcSEcCtD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTM1—kidney cancer	0.00197	0.0137	CbGpPWpGaD
Cyclizine—Bronchospasm—Capecitabine—kidney cancer	0.00195	0.0029	CcSEcCtD
Cyclizine—Agitation—Vincristine—kidney cancer	0.00195	0.00289	CcSEcCtD
Cyclizine—Headache—Pazopanib—kidney cancer	0.00195	0.00288	CcSEcCtD
Cyclizine—Connective tissue disorder—Paclitaxel—kidney cancer	0.0019	0.00282	CcSEcCtD
Cyclizine—SULT1E1—Biological oxidations—CYP1A1—kidney cancer	0.00189	0.0132	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP1A1—kidney cancer	0.00187	0.013	CbGpPWpGaD
Cyclizine—Insomnia—Sunitinib—kidney cancer	0.00185	0.00275	CcSEcCtD
Cyclizine—Paraesthesia—Sunitinib—kidney cancer	0.00184	0.00273	CcSEcCtD
Cyclizine—Convulsion—Vincristine—kidney cancer	0.00184	0.00273	CcSEcCtD
Cyclizine—Hypertension—Vincristine—kidney cancer	0.00183	0.00272	CcSEcCtD
Cyclizine—Constipation—Sorafenib—kidney cancer	0.00182	0.0027	CcSEcCtD
Cyclizine—Pain—Sorafenib—kidney cancer	0.00182	0.0027	CcSEcCtD
Cyclizine—Hypersensitivity—Vinblastine—kidney cancer	0.00181	0.00269	CcSEcCtD
Cyclizine—Eye disorder—Paclitaxel—kidney cancer	0.00181	0.00268	CcSEcCtD
Cyclizine—Hypersensitivity—Everolimus—kidney cancer	0.00181	0.00268	CcSEcCtD
Cyclizine—Asthenia—Vinblastine—kidney cancer	0.00177	0.00262	CcSEcCtD
Cyclizine—Asthenia—Everolimus—kidney cancer	0.00176	0.00261	CcSEcCtD
Cyclizine—Constipation—Sunitinib—kidney cancer	0.00175	0.0026	CcSEcCtD
Cyclizine—Pain—Sunitinib—kidney cancer	0.00175	0.0026	CcSEcCtD
Cyclizine—Hypertension—Gemcitabine—kidney cancer	0.00174	0.00258	CcSEcCtD
Cyclizine—Chills—Paclitaxel—kidney cancer	0.00174	0.00258	CcSEcCtD
Cyclizine—Pruritus—Everolimus—kidney cancer	0.00174	0.00257	CcSEcCtD
Cyclizine—Anaphylactic shock—Vincristine—kidney cancer	0.00173	0.00257	CcSEcCtD
Cyclizine—Thrombophlebitis—Doxorubicin—kidney cancer	0.00171	0.00254	CcSEcCtD
Cyclizine—Nervous system disorder—Vincristine—kidney cancer	0.0017	0.00252	CcSEcCtD
Cyclizine—Asthenia—Erlotinib—kidney cancer	0.0017	0.00252	CcSEcCtD
Cyclizine—Mental disorder—Paclitaxel—kidney cancer	0.0017	0.00252	CcSEcCtD
Cyclizine—Hepatic function abnormal—Doxorubicin—kidney cancer	0.0017	0.00251	CcSEcCtD
Cyclizine—Urticaria—Sorafenib—kidney cancer	0.00169	0.00251	CcSEcCtD
Cyclizine—Erythema—Paclitaxel—kidney cancer	0.00169	0.0025	CcSEcCtD
Cyclizine—Hepatobiliary disease—Capecitabine—kidney cancer	0.00167	0.00248	CcSEcCtD
Cyclizine—Pruritus—Erlotinib—kidney cancer	0.00167	0.00248	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—ACY1—kidney cancer	0.00166	0.0116	CbGpPWpGaD
Cyclizine—Pain—Dactinomycin—kidney cancer	0.00166	0.00246	CcSEcCtD
Cyclizine—Tension—Paclitaxel—kidney cancer	0.00165	0.00245	CcSEcCtD
Cyclizine—Agranulocytosis—Capecitabine—kidney cancer	0.00165	0.00245	CcSEcCtD
Cyclizine—Anaphylactic shock—Gemcitabine—kidney cancer	0.00164	0.00244	CcSEcCtD
Cyclizine—Nervousness—Paclitaxel—kidney cancer	0.00164	0.00243	CcSEcCtD
Cyclizine—Dizziness—Vinblastine—kidney cancer	0.00163	0.00241	CcSEcCtD
Cyclizine—Dizziness—Everolimus—kidney cancer	0.00162	0.0024	CcSEcCtD
Cyclizine—Muscle spasms—Paclitaxel—kidney cancer	0.00162	0.0024	CcSEcCtD
Cyclizine—Hypotension—Vincristine—kidney cancer	0.00162	0.0024	CcSEcCtD
Cyclizine—Nervous system disorder—Gemcitabine—kidney cancer	0.00161	0.00239	CcSEcCtD
Cyclizine—Skin disorder—Gemcitabine—kidney cancer	0.0016	0.00237	CcSEcCtD
Cyclizine—Hepatitis—Capecitabine—kidney cancer	0.00159	0.00236	CcSEcCtD
Cyclizine—Vision blurred—Paclitaxel—kidney cancer	0.00159	0.00236	CcSEcCtD
Cyclizine—Tremor—Paclitaxel—kidney cancer	0.00158	0.00234	CcSEcCtD
Cyclizine—Hypersensitivity—Sorafenib—kidney cancer	0.00157	0.00233	CcSEcCtD
Cyclizine—Insomnia—Vincristine—kidney cancer	0.00157	0.00232	CcSEcCtD
Cyclizine—Dizziness—Erlotinib—kidney cancer	0.00157	0.00232	CcSEcCtD
Cyclizine—Connective tissue disorder—Capecitabine—kidney cancer	0.00156	0.00232	CcSEcCtD
Cyclizine—Paraesthesia—Vincristine—kidney cancer	0.00156	0.00231	CcSEcCtD
Cyclizine—Dermatitis bullous—Doxorubicin—kidney cancer	0.00155	0.0023	CcSEcCtD
Cyclizine—Agitation—Paclitaxel—kidney cancer	0.00155	0.0023	CcSEcCtD
Cyclizine—Headache—Vinblastine—kidney cancer	0.00154	0.00229	CcSEcCtD
Cyclizine—Angioedema—Paclitaxel—kidney cancer	0.00154	0.00228	CcSEcCtD
Cyclizine—Headache—Everolimus—kidney cancer	0.00154	0.00228	CcSEcCtD
Cyclizine—Hypotension—Gemcitabine—kidney cancer	0.00154	0.00228	CcSEcCtD
Cyclizine—Asthenia—Sorafenib—kidney cancer	0.00153	0.00226	CcSEcCtD
Cyclizine—Hypersensitivity—Sunitinib—kidney cancer	0.00151	0.00224	CcSEcCtD
Cyclizine—Pruritus—Sorafenib—kidney cancer	0.00151	0.00223	CcSEcCtD
Cyclizine—Insomnia—Gemcitabine—kidney cancer	0.00149	0.0022	CcSEcCtD
Cyclizine—Eye disorder—Capecitabine—kidney cancer	0.00149	0.0022	CcSEcCtD
Cyclizine—Headache—Erlotinib—kidney cancer	0.00148	0.0022	CcSEcCtD
Cyclizine—Constipation—Vincristine—kidney cancer	0.00148	0.0022	CcSEcCtD
Cyclizine—Pain—Vincristine—kidney cancer	0.00148	0.0022	CcSEcCtD
Cyclizine—Paraesthesia—Gemcitabine—kidney cancer	0.00148	0.00219	CcSEcCtD
Cyclizine—Asthenia—Sunitinib—kidney cancer	0.00147	0.00218	CcSEcCtD
Cyclizine—Somnolence—Gemcitabine—kidney cancer	0.00146	0.00217	CcSEcCtD
Cyclizine—Convulsion—Paclitaxel—kidney cancer	0.00146	0.00217	CcSEcCtD
Cyclizine—Hypertension—Paclitaxel—kidney cancer	0.00146	0.00216	CcSEcCtD
Cyclizine—Pruritus—Sunitinib—kidney cancer	0.00145	0.00215	CcSEcCtD
Cyclizine—Hypersensitivity—Dactinomycin—kidney cancer	0.00143	0.00212	CcSEcCtD
Cyclizine—Chills—Capecitabine—kidney cancer	0.00143	0.00211	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PDHB—kidney cancer	0.00141	0.00987	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—POMC—kidney cancer	0.00141	0.00984	CbGpPWpGaD
Cyclizine—Dizziness—Sorafenib—kidney cancer	0.00141	0.00209	CcSEcCtD
Cyclizine—Constipation—Gemcitabine—kidney cancer	0.00141	0.00208	CcSEcCtD
Cyclizine—Pain—Gemcitabine—kidney cancer	0.00141	0.00208	CcSEcCtD
Cyclizine—Mental disorder—Capecitabine—kidney cancer	0.00139	0.00206	CcSEcCtD
Cyclizine—Asthenia—Dactinomycin—kidney cancer	0.00139	0.00206	CcSEcCtD
Cyclizine—Erythema—Capecitabine—kidney cancer	0.00138	0.00205	CcSEcCtD
Cyclizine—Anaphylactic shock—Paclitaxel—kidney cancer	0.00138	0.00204	CcSEcCtD
Cyclizine—Dizziness—Sunitinib—kidney cancer	0.00135	0.00201	CcSEcCtD
Cyclizine—Nervous system disorder—Paclitaxel—kidney cancer	0.00135	0.002	CcSEcCtD
Cyclizine—Tachycardia—Paclitaxel—kidney cancer	0.00134	0.00199	CcSEcCtD
Cyclizine—Skin disorder—Paclitaxel—kidney cancer	0.00134	0.00198	CcSEcCtD
Cyclizine—Headache—Sorafenib—kidney cancer	0.00133	0.00198	CcSEcCtD
Cyclizine—Muscle spasms—Capecitabine—kidney cancer	0.00133	0.00197	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CCBL1—kidney cancer	0.00133	0.00928	CbGpPWpGaD
Cyclizine—Vision blurred—Capecitabine—kidney cancer	0.0013	0.00193	CcSEcCtD
Cyclizine—Tremor—Capecitabine—kidney cancer	0.0013	0.00192	CcSEcCtD
Cyclizine—Hypotension—Paclitaxel—kidney cancer	0.00129	0.00191	CcSEcCtD
Cyclizine—Headache—Sunitinib—kidney cancer	0.00128	0.0019	CcSEcCtD
Cyclizine—Hypersensitivity—Vincristine—kidney cancer	0.00128	0.00189	CcSEcCtD
Cyclizine—Insomnia—Paclitaxel—kidney cancer	0.00124	0.00185	CcSEcCtD
Cyclizine—Asthenia—Vincristine—kidney cancer	0.00124	0.00184	CcSEcCtD
Cyclizine—Paraesthesia—Paclitaxel—kidney cancer	0.00124	0.00183	CcSEcCtD
Cyclizine—Somnolence—Paclitaxel—kidney cancer	0.00122	0.00181	CcSEcCtD
Cyclizine—Hypertension—Capecitabine—kidney cancer	0.00119	0.00177	CcSEcCtD
Cyclizine—Asthenia—Gemcitabine—kidney cancer	0.00118	0.00175	CcSEcCtD
Cyclizine—Pain—Paclitaxel—kidney cancer	0.00118	0.00174	CcSEcCtD
Cyclizine—Constipation—Paclitaxel—kidney cancer	0.00118	0.00174	CcSEcCtD
Cyclizine—Pruritus—Gemcitabine—kidney cancer	0.00116	0.00172	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GLIPR1—kidney cancer	0.00115	0.00805	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PPAT—kidney cancer	0.00115	0.00805	CbGpPWpGaD
Cyclizine—Dizziness—Vincristine—kidney cancer	0.00115	0.0017	CcSEcCtD
Cyclizine—Drowsiness—Doxorubicin—kidney cancer	0.00114	0.00169	CcSEcCtD
Cyclizine—CYP2C9—Xenobiotics—CYP1A1—kidney cancer	0.00114	0.00796	CbGpPWpGaD
Cyclizine—Nervous system disorder—Capecitabine—kidney cancer	0.00111	0.00164	CcSEcCtD
Cyclizine—Tachycardia—Capecitabine—kidney cancer	0.0011	0.00163	CcSEcCtD
Cyclizine—Skin disorder—Capecitabine—kidney cancer	0.0011	0.00163	CcSEcCtD
Cyclizine—CYP2C9—Tamoxifen metabolism—CYP1A1—kidney cancer	0.0011	0.00765	CbGpPWpGaD
Cyclizine—Urticaria—Paclitaxel—kidney cancer	0.00109	0.00162	CcSEcCtD
Cyclizine—Headache—Vincristine—kidney cancer	0.00109	0.00161	CcSEcCtD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.00108	0.00755	CbGpPWpGaD
Cyclizine—Hepatobiliary disease—Doxorubicin—kidney cancer	0.00108	0.0016	CcSEcCtD
Cyclizine—Flunarizine—CYP1A1—kidney cancer	0.00107	0.138	CrCbGaD
Cyclizine—SULT1E1—Metabolism—APRT—kidney cancer	0.00107	0.00748	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—FH—kidney cancer	0.00107	0.00748	CbGpPWpGaD
Cyclizine—Agranulocytosis—Doxorubicin—kidney cancer	0.00107	0.00158	CcSEcCtD
Cyclizine—Hypotension—Capecitabine—kidney cancer	0.00106	0.00156	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—ACY1—kidney cancer	0.00105	0.00732	CbGpPWpGaD
Cyclizine—Headache—Gemcitabine—kidney cancer	0.00103	0.00153	CcSEcCtD
Cyclizine—Hepatitis—Doxorubicin—kidney cancer	0.00102	0.00152	CcSEcCtD
Cyclizine—Insomnia—Capecitabine—kidney cancer	0.00102	0.00151	CcSEcCtD
Cyclizine—Paraesthesia—Capecitabine—kidney cancer	0.00101	0.0015	CcSEcCtD
Cyclizine—Hypersensitivity—Paclitaxel—kidney cancer	0.00101	0.0015	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GPC3—kidney cancer	0.00101	0.00703	CbGpPWpGaD
Cyclizine—Connective tissue disorder—Doxorubicin—kidney cancer	0.00101	0.00149	CcSEcCtD
Cyclizine—Reboxetine—ABCB1—kidney cancer	0.000997	0.128	CrCbGaD
Cyclizine—Asthenia—Paclitaxel—kidney cancer	0.000987	0.00146	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CA2—kidney cancer	0.000981	0.00684	CbGpPWpGaD
Cyclizine—Pruritus—Paclitaxel—kidney cancer	0.000974	0.00144	CcSEcCtD
Cyclizine—Constipation—Capecitabine—kidney cancer	0.000966	0.00143	CcSEcCtD
Cyclizine—Pain—Capecitabine—kidney cancer	0.000966	0.00143	CcSEcCtD
Cyclizine—Eye disorder—Doxorubicin—kidney cancer	0.000958	0.00142	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—ALAD—kidney cancer	0.000956	0.00667	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ST3GAL2—kidney cancer	0.000933	0.00651	CbGpPWpGaD
Cyclizine—Chills—Doxorubicin—kidney cancer	0.00092	0.00136	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—ALDH1A1—kidney cancer	0.000912	0.00636	CbGpPWpGaD
Cyclizine—Dizziness—Paclitaxel—kidney cancer	0.00091	0.00135	CcSEcCtD
Cyclizine—Mental disorder—Doxorubicin—kidney cancer	0.000898	0.00133	CcSEcCtD
Cyclizine—Urticaria—Capecitabine—kidney cancer	0.000897	0.00133	CcSEcCtD
Cyclizine—Erythema—Doxorubicin—kidney cancer	0.000892	0.00132	CcSEcCtD
Cyclizine—Tension—Doxorubicin—kidney cancer	0.000875	0.0013	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PGK1—kidney cancer	0.000874	0.0061	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—SLC5A3—kidney cancer	0.000874	0.0061	CbGpPWpGaD
Cyclizine—Nervousness—Doxorubicin—kidney cancer	0.000866	0.00128	CcSEcCtD
Cyclizine—Headache—Paclitaxel—kidney cancer	0.000862	0.00128	CcSEcCtD
Cyclizine—Muscle spasms—Doxorubicin—kidney cancer	0.000858	0.00127	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—LDHB—kidney cancer	0.000857	0.00598	CbGpPWpGaD
Cyclizine—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000851	0.00594	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—PTGS1—kidney cancer	0.00085	0.00593	CbGpPWpGaD
Cyclizine—Cinnarizine—CYP1A1—kidney cancer	0.00085	0.109	CrCbGaD
Cyclizine—Vision blurred—Doxorubicin—kidney cancer	0.000841	0.00125	CcSEcCtD
Cyclizine—HRH1—IL-4 Signaling Pathway—BIRC5—kidney cancer	0.00084	0.00586	CbGpPWpGaD
Cyclizine—Hypersensitivity—Capecitabine—kidney cancer	0.000832	0.00123	CcSEcCtD
Cyclizine—Agitation—Doxorubicin—kidney cancer	0.00082	0.00122	CcSEcCtD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000811	0.00566	CbGpPWpGaD
Cyclizine—Asthenia—Capecitabine—kidney cancer	0.00081	0.0012	CcSEcCtD
Cyclizine—Pruritus—Capecitabine—kidney cancer	0.000799	0.00118	CcSEcCtD
Cyclizine—Convulsion—Doxorubicin—kidney cancer	0.000773	0.00115	CcSEcCtD
Cyclizine—Hypertension—Doxorubicin—kidney cancer	0.00077	0.00114	CcSEcCtD
Cyclizine—Dizziness—Capecitabine—kidney cancer	0.000747	0.00111	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CA9—kidney cancer	0.000743	0.00518	CbGpPWpGaD
Cyclizine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000728	0.00108	CcSEcCtD
Cyclizine—Nervous system disorder—Doxorubicin—kidney cancer	0.000714	0.00106	CcSEcCtD
Cyclizine—Tachycardia—Doxorubicin—kidney cancer	0.000711	0.00105	CcSEcCtD
Cyclizine—Headache—Capecitabine—kidney cancer	0.000708	0.00105	CcSEcCtD
Cyclizine—Skin disorder—Doxorubicin—kidney cancer	0.000707	0.00105	CcSEcCtD
Cyclizine—Hypotension—Doxorubicin—kidney cancer	0.00068	0.00101	CcSEcCtD
Cyclizine—Diphenhydramine—PTGS1—kidney cancer	0.000667	0.0856	CrCbGaD
Cyclizine—Insomnia—Doxorubicin—kidney cancer	0.000659	0.000976	CcSEcCtD
Cyclizine—Paraesthesia—Doxorubicin—kidney cancer	0.000654	0.000969	CcSEcCtD
Cyclizine—Somnolence—Doxorubicin—kidney cancer	0.000647	0.000959	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CRABP1—kidney cancer	0.000632	0.00441	CbGpPWpGaD
Cyclizine—Constipation—Doxorubicin—kidney cancer	0.000623	0.000923	CcSEcCtD
Cyclizine—Pain—Doxorubicin—kidney cancer	0.000623	0.000923	CcSEcCtD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000596	0.00416	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—ITPR2—kidney cancer	0.000588	0.0041	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ITPR2—kidney cancer	0.000587	0.0041	CbGpPWpGaD
Cyclizine—Urticaria—Doxorubicin—kidney cancer	0.000578	0.000857	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—ALDH1A1—kidney cancer	0.000575	0.00401	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000548	0.00382	CbGpPWpGaD
Cyclizine—Hypersensitivity—Doxorubicin—kidney cancer	0.000536	0.000795	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GSTT1—kidney cancer	0.000536	0.00374	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ACHE—kidney cancer	0.000536	0.00374	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—RELA—kidney cancer	0.000535	0.00374	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR2—kidney cancer	0.000526	0.00367	CbGpPWpGaD
Cyclizine—Asthenia—Doxorubicin—kidney cancer	0.000522	0.000774	CcSEcCtD
Cyclizine—Pruritus—Doxorubicin—kidney cancer	0.000515	0.000764	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—SCARB1—kidney cancer	0.000507	0.00354	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PTGS1—kidney cancer	0.000502	0.0035	CbGpPWpGaD
Cyclizine—Bepridil—ABCB1—kidney cancer	0.000496	0.0637	CrCbGaD
Cyclizine—HRH1—G alpha (q) signalling events—ANXA1—kidney cancer	0.000493	0.00344	CbGpPWpGaD
Cyclizine—Clozapine—CYP1A1—kidney cancer	0.000492	0.0632	CrCbGaD
Cyclizine—SULT1E1—Metabolism—PSMD7—kidney cancer	0.000492	0.00343	CbGpPWpGaD
Cyclizine—Dizziness—Doxorubicin—kidney cancer	0.000481	0.000714	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—OR4C13—kidney cancer	0.000475	0.00331	CbGpPWpGaD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000474	0.0033	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000467	0.00326	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—BCHE—kidney cancer	0.000467	0.00326	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—SLC5A5—kidney cancer	0.000461	0.00322	CbGpPWpGaD
Cyclizine—Fentanyl—ABCB1—kidney cancer	0.000456	0.0586	CrCbGaD
Cyclizine—Headache—Doxorubicin—kidney cancer	0.000456	0.000676	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—SLC2A1—kidney cancer	0.000445	0.00311	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—kidney cancer	0.000441	0.00308	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—OR4C13—kidney cancer	0.000431	0.00301	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—MAPK3—kidney cancer	0.000388	0.0027	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000384	0.00268	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTP1—kidney cancer	0.000371	0.00259	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—MAPK1—kidney cancer	0.000369	0.00257	CbGpPWpGaD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000353	0.00246	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ABCB1—kidney cancer	0.000352	0.00245	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTM1—kidney cancer	0.000341	0.00238	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTT1—kidney cancer	0.000338	0.00236	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.000326	0.00228	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—PTGS2—kidney cancer	0.000326	0.00227	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CYP1A1—kidney cancer	0.000324	0.00226	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—PIK3CA—kidney cancer	0.00032	0.00223	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—PTGS1—kidney cancer	0.000317	0.00221	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—kidney cancer	0.000286	0.002	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000279	0.00195	CbGpPWpGaD
Cyclizine—Clozapine—ABCB1—kidney cancer	0.000262	0.0336	CrCbGaD
Cyclizine—HRH1—Signaling Pathways—OR4C13—kidney cancer	0.000255	0.00178	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—ANXA1—kidney cancer	0.000249	0.00173	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—POMC—kidney cancer	0.000241	0.00168	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTP1—kidney cancer	0.000234	0.00163	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTP1—kidney cancer	0.000231	0.00161	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LATS1—kidney cancer	0.000217	0.00151	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTM1—kidney cancer	0.000215	0.0015	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	0.000212	0.00148	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	0.000204	0.00142	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	0.000201	0.0014	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—AKAP13—kidney cancer	0.000197	0.00138	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PTGS2—kidney cancer	0.000192	0.00134	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AMER1—kidney cancer	0.000184	0.00128	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ACY1—kidney cancer	0.000179	0.00125	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AKAP13—kidney cancer	0.000179	0.00125	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	0.000178	0.00124	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PTEN—kidney cancer	0.000168	0.00117	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—ITPR2—kidney cancer	0.000168	0.00117	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	0.00016	0.00112	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CER1—kidney cancer	0.000154	0.00108	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GPC3—kidney cancer	0.000154	0.00108	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.000153	0.00107	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PDHB—kidney cancer	0.000153	0.00106	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—ITPR2—kidney cancer	0.000152	0.00106	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—POMC—kidney cancer	0.000152	0.00106	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CCBL1—kidney cancer	0.000143	0.001	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—ANXA1—kidney cancer	0.00014	0.00098	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SFRP2—kidney cancer	0.000131	0.000915	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	0.00013	0.000905	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	0.000128	0.000896	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—ANXA1—kidney cancer	0.000128	0.00089	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GLIPR1—kidney cancer	0.000124	0.000868	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PPAT—kidney cancer	0.000124	0.000868	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	0.000123	0.000857	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	0.000122	0.000852	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—POMC—kidney cancer	0.000122	0.00085	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	0.000122	0.000848	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—PIK3CA—kidney cancer	0.000118	0.000827	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PIK3CA—kidney cancer	0.000118	0.000826	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—APRT—kidney cancer	0.000116	0.000806	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—FH—kidney cancer	0.000116	0.000806	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	0.000115	0.000805	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	0.000113	0.000788	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GPC3—kidney cancer	0.000109	0.000758	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	0.000106	0.000739	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AKAP13—kidney cancer	0.000106	0.000738	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CASP2—kidney cancer	0.000106	0.000738	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CA2—kidney cancer	0.000106	0.000738	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALAD—kidney cancer	0.000103	0.000719	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ST3GAL2—kidney cancer	0.000101	0.000702	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALDH1A1—kidney cancer	9.83e-05	0.000686	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GRB7—kidney cancer	9.67e-05	0.000675	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PGK1—kidney cancer	9.42e-05	0.000657	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC5A3—kidney cancer	9.42e-05	0.000657	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LDHB—kidney cancer	9.24e-05	0.000645	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ITPR2—kidney cancer	8.99e-05	0.000627	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CTNNA1—kidney cancer	8.15e-05	0.000569	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HSPB1—kidney cancer	8.11e-05	0.000565	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EIF4EBP1—kidney cancer	8.11e-05	0.000565	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CA9—kidney cancer	8.01e-05	0.000559	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	7.83e-05	0.000546	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PSMD7—kidney cancer	7.54e-05	0.000526	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TSC1—kidney cancer	7.54e-05	0.000526	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ANXA1—kidney cancer	7.54e-05	0.000526	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FLT1—kidney cancer	7.3e-05	0.000509	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—POMC—kidney cancer	6.88e-05	0.00048	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CRABP1—kidney cancer	6.81e-05	0.000475	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JUNB—kidney cancer	6.77e-05	0.000472	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PAK1—kidney cancer	6.77e-05	0.000472	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ITPR2—kidney cancer	6.33e-05	0.000442	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—POMC—kidney cancer	6.25e-05	0.000436	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.84e-05	0.000407	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTT1—kidney cancer	5.78e-05	0.000403	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ACHE—kidney cancer	5.78e-05	0.000403	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF2—kidney cancer	5.53e-05	0.000386	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN2B—kidney cancer	5.51e-05	0.000384	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SCARB1—kidney cancer	5.47e-05	0.000381	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS1—kidney cancer	5.41e-05	0.000378	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF1R—kidney cancer	5.35e-05	0.000373	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PSMD7—kidney cancer	5.31e-05	0.00037	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—RAF1—kidney cancer	5.15e-05	0.000359	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—IL2—kidney cancer	5.09e-05	0.000355	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—BCHE—kidney cancer	5.03e-05	0.000351	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC5A5—kidney cancer	4.97e-05	0.000347	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC2A1—kidney cancer	4.8e-05	0.000335	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.66e-05	0.000325	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL2—kidney cancer	4.62e-05	0.000322	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIF1A—kidney cancer	4.4e-05	0.000307	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TSC2—kidney cancer	4.39e-05	0.000306	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KDR—kidney cancer	4.21e-05	0.000294	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.06e-05	0.000283	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTP1—kidney cancer	4e-05	0.000279	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APC—kidney cancer	3.88e-05	0.000271	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KIT—kidney cancer	3.88e-05	0.000271	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCB1—kidney cancer	3.79e-05	0.000264	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—MAPK3—kidney cancer	3.71e-05	0.000259	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—POMC—kidney cancer	3.69e-05	0.000258	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTM1—kidney cancer	3.68e-05	0.000257	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—BRAF—kidney cancer	3.65e-05	0.000254	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—MAPK1—kidney cancer	3.53e-05	0.000247	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.49e-05	0.000243	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	3.38e-05	0.000236	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—KRAS—kidney cancer	3.34e-05	0.000233	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	3.07e-05	0.000214	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RAF1—kidney cancer	3.04e-05	0.000212	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RELA—kidney cancer	3.03e-05	0.000211	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ERBB2—kidney cancer	3.01e-05	0.00021	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MTOR—kidney cancer	2.97e-05	0.000207	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.87e-05	0.0002	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1B—kidney cancer	2.79e-05	0.000195	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL2—kidney cancer	2.73e-05	0.00019	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCND1—kidney cancer	2.66e-05	0.000186	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JUN—kidney cancer	2.66e-05	0.000185	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CTNNB1—kidney cancer	2.63e-05	0.000184	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—POMC—kidney cancer	2.6e-05	0.000181	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PTEN—kidney cancer	2.57e-05	0.000179	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VEGFA—kidney cancer	2.32e-05	0.000162	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAPK3—kidney cancer	2.19e-05	0.000153	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MYC—kidney cancer	2.13e-05	0.000149	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAPK1—kidney cancer	2.09e-05	0.000146	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS2—kidney cancer	2.07e-05	0.000145	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KRAS—kidney cancer	1.97e-05	0.000138	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CA—kidney cancer	1.81e-05	0.000126	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTEN—kidney cancer	1.81e-05	0.000126	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TP53—kidney cancer	1.75e-05	0.000122	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.28e-05	8.9e-05	CbGpPWpGaD
